Interstitial Lung Diseases Pipeline Outlook DWN12088 is an investigational therapy for idiopathic ... A deuterated form of ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...

These findings suggest RA-ILD sex differences may be driven by RA-UIP and emphasizes the importance of further studies to clarify RA-ILD heterogeneity and optimize screening and treatment approaches.

12, 2024 — Researchers examined the impact of obesity in relation to treatment and mortality from data on over 500,000 lung cancer patients. This study suggests that immunotherapy may not be the ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

The toxin strychnine, the primary component of the traditional Chinese medicine, may act in the STAT3 pathway, investigators ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Diwali is synonymous with fireworks but such celebrations contribute to air pollution by releasing particulate matter (PM10 ...

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic ...

Tyr Pharma has a pivotal year ahead with key readouts for Efzofitimod, potentially opening a huge market. Find out why ATYR ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy organization, today announced the appointment of Amy Hajari Case, MD, FCCP, as ...